Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) COO Sells 10,000 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total value of $3,649,100.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $940,373.07. The trade was a 79.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Michael Benkowitz also recently made the following trade(s):

• On Monday, January 13th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $364.62, for a total value of $3,646,200.00.
• On Monday, December 30th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $356.68, for a total value of $3,566,800.00.
• On Monday, December 23rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $361.95, for a total value of $3,619,500.00.
• On Monday, November 25th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $372.75, for a total value of $3,727,500.00.
• On Monday, November 11th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The shares were sold at an average price of $407.32, for a total value of $6,109,800.00.
• On Thursday, November 7th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00.
• On Friday, November 1st, Michael Benkowitz sold 14,700 shares of United Therapeutics stock. The stock was sold at an average price of $374.46, for a total value of $5,504,562.00.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $371.89 on Friday. The business has a 50-day moving average of $365.04 and a 200 day moving average of $355.24. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82. The stock has a market capitalization of $16.60 billion, a price-to-earnings ratio of 16.33, a price-to-earnings-growth ratio of 0.94 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. During the same period last year, the business posted $5.38 EPS. United Therapeutics’s revenue for the quarter was up 22.9% on a year-over-year basis. Equities research analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Analysts Set New Price Targets

UTHR has been the subject of a number of recent research reports. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. TD Cowen raised their target price on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. HC Wainwright raised their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. LADENBURG THALM/SH SH raised their target price on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, UBS Group raised their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $378.36.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in shares of United Therapeutics by 4.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock valued at $391,459,000 after buying an additional 45,566 shares during the period. FMR LLC boosted its stake in shares of United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock valued at $386,168,000 after buying an additional 314,004 shares during the period. Pacer Advisors Inc. boosted its stake in shares of United Therapeutics by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company’s stock valued at $210,869,000 after buying an additional 30,931 shares during the period. Janus Henderson Group PLC boosted its stake in shares of United Therapeutics by 12.3% in the 3rd quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company’s stock valued at $164,978,000 after buying an additional 50,409 shares during the period. Finally, Assetmark Inc. boosted its stake in shares of United Therapeutics by 56.9% in the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after buying an additional 152,249 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.